caffeic acid phenethyl ester has been researched along with MeJA in 1 studies
| Studies (caffeic acid phenethyl ester) | Trials (caffeic acid phenethyl ester) | Recent Studies (post-2010) (caffeic acid phenethyl ester) | Studies (MeJA) | Trials (MeJA) | Recent Studies (post-2010) (MeJA) |
|---|---|---|---|---|---|
| 840 | 1 | 469 | 7 | 0 | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Feng, F; Guo, Q; He, S; Liu, W; Liu, Y; Sun, H; Zhao, L | 1 |
1 review(s) available for caffeic acid phenethyl ester and MeJA
| Article | Year |
|---|---|
Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
Topics: Aldo-Keto Reductase Family 1 Member C3; Antineoplastic Agents; Binding Sites; Cell Proliferation; Clinical Trials as Topic; Drug Development; Drug Resistance, Neoplasm; Humans; Models, Molecular; Molecular Structure; Neoplasms; Treatment Outcome | 2020 |